NIAGEN BIOSCIENCE, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.1M | $67.4M | $59.3M | $46.3M | $31.6M |
| Cost of Revenue | $46.2M | $38.0M | $32.8M | $29.3M | $26.0M | $24.0M | $20.5M | $15.5M |
| Gross Profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M | $35.3M | $25.8M | $16.1M |
| Gross Margin | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% | 55.7% | 50.9% |
| Operating Expenses | ||||||||
| Research & Development | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M | $3.4M | $4.4M | $5.5M |
| SG&A Expense | $27.1M | $18.4M | $25.0M | $28.3M | $36.4M | $30.8M | $34.3M | $27.1M |
| Operating Income | $16.3M | $7.7M | $-5.6M | $-18.6M | $-27.1M | $-19.9M | $-31.3M | $-33.2M |
| Operating Margin | 12.6% | 7.8% | -6.7% | -25.9% | -40.1% | -33.5% | -67.6% | -105.1% |
| Interest Expense | — | — | — | — | $55.0K | $71.0K | $847.0K | $79.0K |
| Pretax Income | $18.2M | $8.9M | $-4.9M | — | — | — | — | — |
| Income Tax Expense | $810.0K | $305.0K | $0 | — | — | — | — | — |
| Net Income | $17.4M | $8.6M | $-4.9M | $-16.5M | $-27.1M | $-19.9M | $-32.1M | $-33.3M |
| Net Margin | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% | -69.4% | -105.6% |
| EPS (Basic) | $0.22 | $0.11 | $-0.07 | $-0.24 | $-0.40 | $-0.33 | $-0.56 | $-0.61 |
| EPS (Diluted) | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 | $-0.33 | $-0.56 | $-0.61 |
| Shares Outstanding (Basic) | 79.2M | 75.9M | 75.0M | 69.7M | 67.2M | 61.1M | 59.6M | 55.1M |
| Shares Outstanding (Diluted) | 85.4M | 78.1M | 75.0M | 69.7M | 67.2M | 61.1M | 59.6M | 55.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |